Joanna C. Chan
Melbourne, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 12, 2026
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.
Journal: Nature communications
Published: November 21, 2025
Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells.
Journal: medRxiv : the preprint server for health sciences
Published: November 19, 2025
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.
Journal: The Lancet. Oncology
Published: October 07, 2025
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.
Journal: The Lancet. Oncology
Published: August 07, 2025
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.
Journal: The Lancet. Oncology
Published: April 17, 2025
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer.
Journal: Nature communications
Published: February 05, 2025
Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: August 23, 2024
Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease Progression.
Journal: JCO oncology practice
Published: June 26, 2020
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 09, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026